PrimeRFP SCOUT · Federal Contract Recompete Brief

HHSO100201700020COTA regeneron other transaction authority — Regeneron Pharmaceuticals, Inc

Regeneron Pharmaceuticals, Inc holds $-7,005,694 across 6 federal awards. The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: Unrestricted. Recompete timing centers on the Sep 25, 2027 PoP end — agencies typically plan 12–18 months ahead.

Barda - Aspr / Daappo / Barda Dcma

Awarding office

Regeneron Pharmaceuticals, Inc

Recipient

Sep 25, 2027

PoP end

$-5,999,058.17

Obligated

541711

NAICS

AN13

PSC

Unrestricted

Set-aside

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

Unrestricted

Contract numberHHSO100201700020C

AgencyBarda - Aspr / Daappo / Barda Dcma

Awarding officeBarda - Aspr / Daappo / Barda Dcma

IncumbentRegeneron Pharmaceuticals, Inc

UEIN3F9MH7E6HD6

NAICS541711

No full NAICS 541711 intel page yet. Browse NAICS intelligence

PSCAN13

Place of performanceTARRYTOWN, NY

Related solicitationBAA16100SOL00002

PoP end (current)Sep 25, 2027

Obligated$-5,999,058.17

Regeneron Other Transaction Authority (OTA) Award is a federal Unrestricted award for Barda - Aspr / Daappo / Barda Dcma held by Regeneron Pharmaceuticals, Inc. Estimated value $611.3M ($-5,999,058.17 obligated). Current period of performance ends Sep 25, 2027. Last award drew 1 bidder. Place of performance: TARRYTOWN, NY. Related solicitation BAA16100SOL00002.

Regeneron other transaction authority (ota) award. Latest action is a modification.

Recompete timing

Public

● Expiring in 342 days

Current PoP ends Sep 25, 2027 (342 days remaining). Agencies typically plan 12–18 months ahead — at 11.2 months out, that window is already open. The buying decision is likely already in motion.

Want the durability read on HHSO100201700020C? One Pursuit Analysis, $500, inside 48 business hours.

48 business hours
$500
Credits toward the Pack

Buy one Pursuit Analysis — $500

Incumbent footprint

Public record

Regeneron Pharmaceuticals, Inc — $-7,005,694 obligated across 6 awards (firm-wide, all agencies).

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract HHSO100201700020C?

HHSO100201700020C (OTA regeneron other transaction authority) is a Barda - Aspr / Daappo / Barda Dcma award with an estimated value of $611.3M, currently held by Regeneron Pharmaceuticals, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded HHSO100201700020C?

Barda - Aspr / Daappo / Barda Dcma awarded HHSO100201700020C to Regeneron Pharmaceuticals, Inc.

Who is the incumbent on HHSO100201700020C?

Regeneron Pharmaceuticals, Inc is the incumbent with $-7,005,694 across 6 related awards in SCOUT’s public footprint. The current period of performance ends Sep 25, 2027.

When does Regeneron Pharmaceuticals, Inc’s HHSO100201700020C come up for recompete?

SCOUT tracks a period-of-performance end of Sep 25, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on HHSO100201700020C? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Oct 12, 2026 · refreshed monthlyLatest procurement action Sep 16, 2026